Fulcrum Therapeutics (NASDAQ:FULC) Director Sells $65,700.00 in Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) Director Alan Ezekowitz sold 18,000 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director owned 10,927 shares in the company, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Fulcrum Therapeutics Stock Down 1.9%

Shares of NASDAQ FULC traded down $0.07 on Tuesday, reaching $3.66. 2,421,701 shares of the company’s stock traded hands, compared to its average volume of 1,644,518. Fulcrum Therapeutics, Inc. has a 12 month low of $2.83 and a 12 month high of $15.74. The business’s 50 day simple moving average is $5.66 and its two-hundred day simple moving average is $8.25. The company has a market cap of $243.87 million, a price-to-earnings ratio of -3.18 and a beta of 2.93.

Get Fulcrum Therapeutics alerts:

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last released its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. Analysts forecast that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new position in Fulcrum Therapeutics during the 1st quarter valued at about $292,000. Westshore Wealth LLC bought a new stake in shares of Fulcrum Therapeutics in the first quarter worth approximately $130,000. The Manufacturers Life Insurance Company raised its holdings in shares of Fulcrum Therapeutics by 25.0% during the first quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company’s stock valued at $124,000 after purchasing an additional 3,219 shares during the last quarter. Pale Fire Capital SE bought a new position in Fulcrum Therapeutics during the first quarter valued at approximately $200,000. Finally, Siren L.L.C. lifted its position in Fulcrum Therapeutics by 20.5% during the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 400,000 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Citigroup cut shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday, June 2nd. Truist Financial downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $8.20.

View Our Latest Analysis on Fulcrum Therapeutics

Fulcrum Therapeutics Company Profile

(Get Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

Featured Stories

• Five stocks we like better than Fulcrum Therapeutics
• NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
• Amazon Could Be About to Reap the Rewards of a Software Spending Boom
• Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
• AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.